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ABSTRACT
OBJECTIVE: To develop a model to assess different strategies of pertussis 
booster vaccination in the city of São Paulo.
METHODS: A dynamic stationary age-dependent compartmental model with 
waning immunity was developed. The “Who Acquires Infection from Whom” 
matrix was used to modeling age-dependent transmission rates. There were 
tested different strategies including vaccine boosters to the current vaccination 
schedule and three of them were reported: (i) 35% coverage at age 12, or (ii) 
70% coverage at age 12, and (iii) 35% coverage at age 12 and 70% coverage 
at age 20 at the same time.
RESULTS: The strategy (i) achieved a 59% reduction of pertussis occurrence 
and a 53% reduction in infants while strategy (ii) produced 76% and 63% 
reduction and strategy (iii) 62% and 54%, respectively.
CONCLUSION: Pertussis booster vaccination at age 12 proved to be the best 
strategy among those tested in this study as it achieves the highest overall 
reduction and the greatest impact among infants who are more susceptible to 
pertussis complications.
DESCRIPTORS: Pertussis Vaccine, administration & dosage. Whooping 
Cough, prevention & control. Immunization Coverage. Mathematical 
Models.
Artigos Originais
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Whooping cough in infants can be clinically severe and 
progress to complications or sequelae including death. 
Immunization is complete after booster vaccination at 
the age of two and progressively wanes out by the age 
of six to 12. Pertussis reservoirs are infected people or 
asymptomatic carriers, either children or adults. Thus, 
disease may go undiagnosed. While whooping cough is 
often clinically exuberant in children, it can present as a 
chronic cough in adults.24 Postels-Multani et al19 reported 
30.7% of undiagnosed pertussis infection in adults, of 
which 8% presented with typical whooping cough.
The Pan American Health Organization (PAHO) 
estimates that every year 20 to 40 millions people are 
affected globally.18 Of these, 200 to 400 thousands die 
of pertussis, 90% in developing countries. These deaths 
are not evenly distributed by age and the great impact 
on infants has been long acknowledged. According Hill 
(1933),13 “...improvement in the death-rates over the 
last seventy years, though very considerable at all ages 
under fi ve, was least in infancy and most at ages over 
two years”. Pertussis is primarily controlled through 
vaccination. Mass immunization began in the 1950s 
when the diphtheria-tetanus-pertussis (DTP) vaccine 
RESUMO
OBJETIVO: Desenvolver um modelo capaz de acessar resultados de diferentes 
possíveis estratégias de reforço vacinal contra a coqueluche, na cidade de São 
Paulo.
MÉTODOS: O modelo matemático dinâmico proposto é dependente da idade 
e considerou perda da imunidade vacinal com o avanço da idade. A matriz 
“who acquire infection from whom” foi utilizada para inserir as diferentes 
dinâmicas de contatos entre os grupos etários. Diferentes estratégias vacinais 
foram testadas, acrescentando reforços vacinais ao atual esquema utilizado, e 
três diferentes estratégias foram reportadas: (i) 35% ou (ii) 70% de cobertura 
vacinal na idade de 12 anos e (iii) coberturas vacinais de 35% aos 12 anos e 
70% aos 20 anos ao mesmo tempo.
RESULTADOS: A estratégia (i) produziu redução de 59% nos casos de coqueluche 
e 53% de redução entre os menores de um ano; a estratégia (ii) alcançou redução 
de 76% nos casos e de 63% entre os menores de um ano; a estratégia (iii) reduziu 
em 62% o total de casos e 54% entre os menores de um ano.
DISCUSSÃO: Reforço vacinal contra a coqueluche aos 12 anos é a melhor 
estratégia dentre as testadas, pois gera maior redução de casos em todas as idades 
e alcança maior impacto entre os menores de um ano, os mais vulneráveis às 
complicações da coqueluche.
DESCRITORES: Vacina contra Coqueluche, administração & dosagem. 
Coqueluche, prevenção & controle. Cobertura Vacinal. Modelos 
Matemáticos.
INTRODUCTION
a Shimizu SMM, Espindola LCF. Adolescent hepatites B vaccine coverage at São Paulo City:2001 to 2005 [essay]. São Paulo: Faculdade de 
Saúde Pública da Universidade de São Paulo; 2006.
was implemented in different countries leading to a 
reduction greater than 90% in disease incidence and 
mortality.24 A regular pertussis vaccination program was 
introduced in Brazil in the 1970s. The vaccine schedule 
consists of three doses for infants and boosters at 15 to 
18 months and fi ve to six years of age. There has been 
reported coverage greater than 90% for infants and 
booster vaccine coverage estimated at 82% and 89% 
for 15-18 month-olds and 5-6 year-olds, respectively, 
in the last decades in Brazil.a
Although effective for disease prevention, pertussis 
vaccination does not prevent bacteria circulation even 
when coverage is high.24 In the last ten to 20 years, 
despite adequate vaccination coverage, many countries 
reported disease outbreaks with increasing incidence 
among adolescents and adults,11,17,24 which in turn 
increases the risk of infection in infants.11,23,24
The possible causes of this reemergence are: progressive 
loss of immunity as vaccinated children grow older; 
improved medical diagnosis; reduction of vaccination 
effect; potential genetic changes in Bordetella pertussis, 
improved epidemiological surveillance, and availability 
of more accurate diagnostic tests.4 In fact, recent studies 
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b Ministério da Saúde. DATASUS. Série histórica de casos de óbitos de doenças de notifi cação compulsória – Brasil. 1980 a 2005 [cited 2007 
Jan 2]. Available from: http://portal.saude.gov.br/portal/arquivos/pdf/planilhas_dnc_casos_e_obitos_todas_2006.pdf
c Secretaria de Estado da Saúde de São Paulo, Centro de Vigilância Epidemiológica “Prof. Alexandre Vranjac”. Coqueluche: distribuição de 
casos confi rmados, óbitos, coefi ciente de incidência e letalidade, segundo ano de início de sintomas e faixa etária, Estado de São Paulo, 2000 
a 2011 [cited 2008 Apr 20]. Available from: http://www.cve.saude.sp.gov.br/htm/resp/coque_tab.htm
on genetic changes conducted in Japan, Canada, US 
and several European countries have suggested that 
though these changes are detected they cannot explain 
the increase in whooping cough rates.4,10,11
The annual incidence rate of whooping cough in Brazil 
was 30 x 10-5 in 1980. Since the introduction of regular 
children vaccination, this rate steeply declined to 1 x 
10-5 and less than 2,000 cases are reported each year 
since 1996.b In the state of São Paulo, southeastern 
Brazil, the annual incidence rate by age from 2000 to 
2007 showed that infants are the most affected.c The 
incidence rate in 2002 was 7.43 x 10-5 and an increasing 
number of cases are reported every year, reaching 16.6 
x 10-5 in 2005 when an outbreak was detected. Children 
aged one to four years are the second most affected 
group with rates ranging from 0.2 to 0.3 x 10-5 in recent 
years. The rates in other age groups mainly reported in 
2001, 2005 and 2007 were not as high. This is in agree-
ment with a known cyclic behavior of pertussis disease 
which could produce peaks every three to four years 
even when there is high vaccine coverage.7
Current surveillance data in Brazil do not show a 
signifi cant rise in pertussis incidence rates. However, 
these data are not reliable since several clinical forms of 
pertussis are not easily diagnosed, and because pertussis 
incidence is passively reported in Brazil. Luz et al17 
modeling of pertussis epidemic in Rio de Janeiro, south-
eastern Brazil, showed a 31% increase in pertussis cases 
by the year 2020 assuming that the current pertussis 
vaccination schedule in Brazil remains unchanged.
This study aimed to develop a model to assess different 
strategies of pertussis booster vaccination.
METHODS
A model was proposed and constructed based on the 
classical susceptible-infected-removed (SIR) disease 
model.1 This is a dynamic stationary age-dependent 
compartmental model with waning immunity after 
disease or vaccine designed to assess whooping cough 
dynamics across age groups in different scenarios of 
pertussis booster vaccination at ages 12 and 20 in the 
city of São Paulo. Disease behavior was assumed steady 
over time, i.e., frequency distribution of subsets within 
compartments do not change over time. The model 
(Figure 1), described by a system of differential equa-
tions, was designed with fi ve compartments, each one 
with subsets of the age groups studied. The assumption 
of steady epidemiological profi le was not preposterous 
since a narrow time period was considered and a few 
decades would be required to assess changes over time.
The following differential equations describe the 
dynamics suggested in Figure 1:
where  was the transmission 
rate (λi) for a given age group a = i from all j age groups 
according to j’s contact rate (βij) and j’s infected compart-
ment (I). Seven different values (a = 1, 2, …7) of age 
groups were used according to the categories as defi ned 
in the Brazilian health database (DATASUS) (<1 year; 
1 to 4; 5 to 9; 10 to 14; 15 to 19; 20 to 39; 40 or more). 
This is a realistic approach that can provide information 
where age is a discrete variable, though higher accuracy 
was sought through calculation of monthly rates.
The compartments were: primary susceptible (Sp) (indi-
viduals with no previous exposure to either pertussis 
bacteria or vaccine, given the mean live birth rate in 
the city of São Paulo in the last fi ve years); infected 
(I) (individuals infected with Bordetella pertussis who 
became ill and infective; the estimated whooping cough 
incidence rates, adjusted to ages groups, in the city of 
São Paulo); vaccinated (V) (vaccinated individuals 
Sp  I  R  V
Ss
pv1(a)
pv2(a)
(a)O J(a)
D1 D2ȝd(a) P(a) 
P(a)
P(a)
(a)OP(a)
Figure 1. Whooping cough age-dependent compartmental 
model. 
Sp: primary susceptible; Ss: secondary susceptible; I: infected; 
R: recovered from disease and immune; V: immune after 
vaccine; λ(a): age-dependent transmission rate; γ(a): age-
dependent recovery rate; α1 and α2: rates of waning immunity; 
pv1(a) and pv2(a): age-dependent immunization rates; μ(a): 
age-dependent mortality rate; μd(a): age-dependent pertussis 
mortality rate.
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within an estimated eight-year window of protection); 
recovered (R) (individuals who recovered from disease 
within an estimated 12–year window of protection); 
secondary susceptible (Ss) (individuals who became 
susceptible after being immune by either disease or 
vaccine).
Transmission rate or force of infection, (λ (a)) defi ned 
for each age group, ascertained the speed at which 
cases of disease were brought into this group from all 
age groups included in the susceptible compartments 
(Sp & Ss) according to effective contact rates (βij) and 
number of infected people (Ij).
(λ (a)): <1 year = 33.5 x 10-5; one to four years = 0.94 x 
10-5; fi ve to nine years = 2.43 x 10-5; ten to 14 years = 
2.62 x 10-5; 15 to 19 years = 3.77 x 10-5; 20 to 39 years 
= 0.59 x 10-5; and >40 years = 0.32 x 10-5.
It was thus designed to take into consideration differ-
ences by age but not the nature of susceptibility 
(primary or secondary). One could wonder whether 
incidence rates in primary susceptible could be 
greater than in secondary susceptible individuals. 
Nevertheless, given the high coverage of DTP vaccine 
in children in São Paulo, primary susceptible indi-
viduals were mainly restricted to infants who have not 
achieved proper age for vaccination, and secondary 
susceptible ones were older individuals with incidence 
rate differences adjusted for age.
As there was no appropriate data on incidence rate 
available in São Paulo, the estimates for the infected 
compartment according to age group (Ij) was based 
on data from the city of Ribeirão Preto, southeastern 
Brazil. Ribeirão Preto is a large city in the state of São 
Paulo with similar patterns of social exposures, and 
had an active epidemiological surveillance system 
for whooping cough. Cases were those with clinically 
suspected pertussis, confi rmed through oropharyngeal 
swab culture or by evidence of exposure to previously 
confi rmed case.
Crude incidence rates were calculated at a monthly 
basis and standardized by the reference age group of 
less than one year in 2005. Data for the last available 
six years were processed and mean ages were estimated 
as the initial transmission rate, or force of infection (λ 
(a)) using Berkeley Madonna® software. A numerical 
solution taking into account the age groups of São 
Paulo population ascertained the number of infected 
individuals by age group (Ij) .
The contact rate (βij) estimated the probability that 
an individual gets infected through this exposure. 
Anderson & May2 Who Acquires Infection from Whom 
(WAIFW) matrix was used to assess the impact of 
exposure on each age group (Figure 2). Suggestions 
for effective exposure rates (βij) were taken from a 
study conducted by Baptista et al.3 This study assessed 
vaccine effi cacy and sources of infection in infants 
providing patterns of exposure across age groups.
Determinant calculus was used to estimate contact rate 
βij by means of equation 6. Both vectors (λ)and Ij had 
seven components related to seven age groups. Ij was 
calculated by the equation 2 using the force of infection 
λi = (λ (a)) and assuming no new vaccine introduction.
The recovery rate 
 
assessed the rate of moving from the Infected (I) to 
the Immune compartment after disease (R) regardless 
of clinical status (active and inactive disease). It was 
calculated as the inverse of the mean time an individual 
is supposedly infective after being infected. The refer-
ence values were taken from Edwards & Decker.7 
Simulations showed that few children reached the 
age of 10 without being exposed to either vaccine or 
disease, and that few cases of disease among these 
came from the secondary susceptible compartment. 
The recovery rate was assessed on a monthly basis (<10 
years = 1.71 and ≥10 years = 3.53).
The rate at which immunity wanes
 ascertained 
speed of migration from the compartments of immune 
individuals (R and V) to that of secondary susceptible 
(Ss) on a monthly basis [after disease (α1) = 1/144 
months (12 years) = 0.0069 and after vaccine (α2) = 
1/96 months (8 years) = 0.0104]. The assumption of 
the ages eight and 12 was based on a recent literature 
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Figure 2. The Who Acquires Infection From Whom (WAIFW) matrix showing the estimated effective contact rates (βij) across 
age groups. City of São Paulo, southeastern Brazil.
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review study by De Carvalho & Pereira.4
The age-dependent mortality rate (μ(a)) assessed the 
rate at which individuals exited the system due to 
death regardless of its causes. It was estimated as mean 
monthly mortality rate in the age groups in São Paulo 
from 2000 to 2004 (<1 year = 13.3 x 10-4; one to four 
years = 0.5 x 10-4; fi ve to 14 years = 0.2 x 10-4; 15 to 
39 years = 1.7 x 10-4; 40 to 49 years = 3.8 x 10-4; 50 to 
59 = 7.9 x 10-4; and >60 years = 26 x 10-4).
The age-dependent pertussis mortality rate (μd(a)) deter-
mined disease fatality on a monthly basis. São Paulo 
health authorities reporteda a yearly fatality rate of 17.5 
10–3 among infants and no deaths in any other age group. 
Thus, monthly age-dependent pertussis mortality rate 
was applied only to infants as μd(infants) = 0.1510–3.
The age-dependent immunization rates (pv1 (a) & pv2 
(a)) assessed the effect of vaccination according to age, 
vaccine coverage, and effi cacy. They refl ected how fast 
individuals from primary susceptible and secondary 
susceptible compartments moved to the vaccinated 
compartment. It was assumed an 80% vaccine effi -
cacy.7,22 The rate pv1(a) described the transition from 
compartment Sp (primary susceptible) to V (vaccinated) 
in the ages two to six months. The rate pv2(a) described 
the transition from compartment Ss (secondary suscep-
tible) to V (vaccinated) in the ages 15 to 18 months 
(fi rst booster) and four to six years (second booster) in 
the current vaccination schedule. When new booster 
vaccinations were introduced for adolescents, pv2(a) 
described these transitions at these ages.
The pv1 and pv2 values were drawn from the numeric 
calculus obtained from each iteration step during inte-
gration of differential equations. It provided the right 
number of individuals moving from the susceptible to 
the vaccinated compartment based on vaccine effi cacy 
and coverage for each age group vaccinated. Coverage 
rates were conservatively set at 35% based on data from 
the current hepatitis B vaccine coverage in adolescents 
in the city of São Paulo, and a more vigorous scenario 
was considered by doubling this fi gure (70%).
Basic reproduction ratio by age group (R0,i) was 
assessed using the equation provided by Anderson 
& May.2 This calculus showed which age group was 
responsible for disease dissemination.
, where
γ(i) = recovery rate in the ith age group;
N(i) = = population in the ith age group;
β(i,a) = is the matrix βij referred above.
Data was retrieved from public databases (DATASUS, 
Ministry of Health) and databases at the state level 
(Epidemiological Surveillance System, São Paulo 
State Health Department). General data on disease 
behavior including infection and immunity duration 
were obtained from the literature.
Different intervention strategies were tested with the 
use of the Berkeley Madonna® (integration of differ-
ential equations) and Microsoft Excel® (impact of new 
dose vaccine on all age groups) in successive iterations 
(Appendix 1 and Appendix 2). The scenarios tested 
were based on the current vaccination schedule in Brazil 
(National Immunization Program): DTP at two, four, and 
six months; DTP booster at 15 to 18 months; DTP booster 
at four to six years of age. Boosters at 12 and/or 20 years 
were examined according to different coverage rates.
Effective vaccination by age group (vaccine coverage 
plus vaccine effi cacy) was applied to susceptible (Sp, 
Ss) individuals to provide the number of immunized (V) 
using the Madonna function “squarepulse,” an adapted 
Dirac delta function. The effects on the age groups were 
assessed in Excel using the WAIFW matrix (Appendix 
1). This second step corrected Madonna output that does 
not evaluate the effect on age groups younger than those 
at which booster vaccination is introduced.
A second Appendix was added to describe step 5 in 
the Appendix 1 concerning adjustment of the infected 
compartment. It describes the procedures for correcting 
the number of infected individuals which could be 
overlooked otherwise. We were not able to estimate 
the baseline number of infected (expected number in 
a non-vaccinated population) because the population 
was being actively vaccinated. The initial βij matrix was 
tainted by existing immunization and, correction was 
needed to avoid overestimating the effect of vaccine 
introduction (repeat vaccination).
The model was validated by correctly simulating the 
average of the last six years pertussis incidence rate 
by age group Ribeirão Preto before running the model 
with São Paulo data.
Changes in parameters were tested (sensitivity analysis):
Crude incidence rate: tested against the standardized 
λ(a) as previously described;
Recovery rate without controlling for age: calculated 
as a single γ = 1,71 tested against stratifi ed recovery 
rate as previously described;
Age-dependent pertussis mortality rate reduced to μd = 
0.10 × 10–3 tested against the original μd = 0.15 × 10–3.
The WAIFW matrix was not included in the sensitivity 
analysis for lack of a valid alternative. The WAIFW 
matrix used was designed based on assumptions 
from the literature and a Brazilian study,3 as formerly 
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described. If any alternative were to be tested, it should 
have a more solid ground that the one considered and, 
thus, rather than taken for sensitivity analysis should 
replace the initial choice at once.
RESULTS
After testing of different scenarios of vaccine coverage 
and ages for booster vaccination, the results converged 
to three solutions summarized trends. Table 1 shows the 
basic reproduction ratio (R0) and expected whooping 
cough reduction by age group.
Young adult vaccine booster did not seem to add a 
signifi cant impact to adolescent booster even with a 
high coverage at this age. A single adolescent booster 
may provide substantial reduction of overall pertussis 
occurrence and can particularly contribute with disease 
reduction among infants. The basic reproduction ratio 
(R0) suggests that for a non-immunized population 
individuals aged less than one year and fi ve to nine years 
would likely spread the disease. Since they are already 
targeted in the current vaccination schedule, it would 
be reasonable to consider that disease spread could 
move forward to the next age group. This is consistent 
with the fi nding that booster vaccination at the age of 
12 provides the best results.
Based on the previously defi ned conditions for sensi-
tivity analysis, if crude incidence rates were used, 
booster vaccination of 12-year-olds would require 90% 
coverage to achieve a reduction that would mostly be 
seen among adolescents. Among infants, it would have 
an impact lower than 10%. A 95% of coverage would 
be required for a booster vaccination of 12-years-old 
to achieve a 20% reduction among infants. If a booster 
vaccination of 20–years-old were added, the impact 
among infants would be no more than 27% reduction 
(Table). This suggests that the model was sensitive to 
changes in incidence rate estimates. The standardization 
of raw data was an important adjustment procedure that 
is required when dealing with incomplete or scarce 
raw data. The model was not sensitive to changes in 
recovery rate and fatality rate.
DISCUSSION
The proposed model is an effi cient tool for evaluating 
the introduction of booster vaccination when there is 
little information available. Resorting to the available 
data and current knowledge, and using procedures 
of standardization and stratifi cation some nontrivial 
conclusions were achieved. The intuitive idea that adult 
vaccination should improve disease control was found 
to be of little importance while booster vaccination of 
adolescents can provide important results when there 
is good coverage. Forsyth9 pointed out that though high 
coverage of adult vaccination can reduce adult cases 
high compliance with this initiative is not expected 
since public awareness about the disease is low. Apart 
from its feasibility, adult vaccination is expensive 
and may not be cost-effective as suggested by Lee et 
al.16 They tested different strategies assessing cost per 
case prevented and cost per quality-adjusted life years 
saved by means of a Markov model and concluded that 
adolescent vaccination seemed preferable.
Van Rie & Hethcote21 and Coudeville et al5 studies on 
adolescent booster vaccination suggested that a reduc-
tion would be expected in those younger than 20 and 
those older than 40 but at the expense of an increase 
among individuals aged 20 to 40, which would recom-
mend a young adult booster vaccination. This contrasts 
with our results but these authors used much lower 
infant transmission rates than those studied here. In 
addition, the age groups were different: transmission 
rates in those one to 18 were twice as high as that in 
those less than one year, making it a tabula rasa of 
immunity waning over one to 18 years of age. Van 
Table. The basic reproduction ratio (R0) by age group and expected whooping cough reduction (%) by age group, and standardized 
or crude incidences rates in the city of São Paulo after the introduction of booster vaccination at given ages and coverage. São 
Paulo, Southeastern Brazil, 2007.
Standardized incidence rate Crude incidence rate
Age group 
(years)
R0
Vaccine 
coverage
35% in 
12–year-
olds (%)
70% in 
12-year-
olds (%)
35% in 12-year-olds
70% in 20-year-olds 
(%)
90% in 
12-year-
olds (%)
95% in 
12–year-
olds (%)
95% in 12-year-olds
90% in 20–year-olds 
(%)
<1 1.75 53 66 54 9 20 27
1 to 4 0.50 56 78 67 29 29 43
5 to 9 1.31 67 78 63 31 46 46
10 to 14 0.71 68 82 71 62 69 69
15 to 19 0.61 66 80 66 48 57 61
20 to 39 0.20 61 75 69 28 39 57
>40 0.13 56 76 64 17 25 42
Total 59 73 62 21 32 40
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Boven et al20 emphasized the importance of taking into 
consideration waning immunity when investigating the 
causes of the 1996–1997 pertussis epidemics in the 
Netherlands. They constructed a time-and age-depen-
dent dynamic model and found that an increased rate 
of waning immunity was a major factor associated with 
the outbreak probably due to some pathogen change. 
The same emphasis on waning immunity and pathogen 
changes was recently given in a study of pertussis 
epidemiological profi le in Poland and Argentina.12,14
Van Rie & Hethcote21 study showed that concomitant 
adolescent and young adult booster vaccination seem 
to signifi cantly reduce pertussis rates in all age groups 
including infants. Nevertheless, similar to Coudeville et 
al5 results, no evidence of any important contribution of 
an added young adult vaccination was shown over single 
vaccination of adolescents. This is relevant in the case 
of São Paulo, not only from a cost perspective but also 
concerning compliance since the current adult diphtheria 
and tetanus (dT) vaccine booster coverage is lower than 
10%.d Assuring adequate immunization coverage of 
adults would be a even greater challenge than that of 
adolescents. Both these studies considered alternative 
schedules as “cocoon strategy” or regular boosters at 
fi xed times which were not examined in the current study.
Edwards & Halasa8 acknowledged the increase in 
pertussis incidence and suggested that each country 
should have a tailored monitoring system and develop 
the most effective strategy based on their own data. 
Although mathematical modeling is a well-established 
epidemiological tool since Kermack & McKendrick15 
seminal paper in 1927, there are few pertussis modeling 
experiences in the literature, they are all limited because 
a unclear association of many factors in pertussis epide-
miology, and they are all hardly comparable, as recently 
pointed out by Crowcroft & Pebody.6 Tackling pertussis 
demands local efforts for understanding disease 
behavior. The Global Pertussis Initiative10 emphasizes 
that research and discussion should focus on “preventing 
infant morbidity and mortality from pertussis and 
tailoring strategies to fi t the needs of each country”.
As in any study based on the axiomatic method, infer-
ence is limited by the model’s premises. An adolescent 
booster vaccination should be considered under the 
light of each and every item of methodological defi ni-
tion discussed in the methods. They were built upon the 
best available information, but were any of them (e.g., 
stationary model, borrowed transmission rates, or else) to 
be disputed and different conclusions could be achieved.
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At the software Madonna,
calculate the new n° of infected
per age group with the current
vaccines doses.
At the Madonna, calculate the
new n° of infected
per age group, adding the new 
booster(s)
Repeat steps 4, 5 and 6 in 
successive iterations until 
the convergence of the 
values
Multiply lj** by the 
corresponding adjusting 
factor (af)
At the Excel®: Ij*xȕij = Ȝi*
At the Excel®: Ija**xȕij = Ȝi**
At Excel reduce estimated lj at the 
age group(s) at which booster(s) is 
introduced, according to pv1 and pv2
Step 1
Step 3
Step 4
Step 6
Back to Step 5
Back to Step 6
Back to Step 4
Step 5
Step 2
lj
lj*
lj**
lja**
lj**
1,lj**
2...lj**
n
lja***
1,lja***
2...lja***
n
Ȝi*
Ȝi
Ȝi**...Ȝi***n
Appendix 1. Steps for the estimation of force of infection (λi)and number of infected people (Ij) after the introduction of booster 
vaccination in adolescents and young adults.
i: age-dependent transmission rate, Ij: number of infected by age group, Ija: adjusted number of infected by age group, βij: 
WAIFW matrix, af: adjusting factor (see Appendix 2), * (uppercase asterisk) means updated parameter.
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Step 1
WAIFW matrix 
calculus
Ij values for São Paulo
city without any pertussis
vaccine
Calculus of the Ij values for São 
Paulo city with current vaccine 
doses at 2, 4, 6, 15 and 60 months 
of age (Madonna®)
Step 2 – appendix 1 
Without booster 
introduction
Estimated 
current
Ij for São Paulo 
city
Step 4 appendix 1 
Without booster 
introduction
Since the correct Ij** must be = Ij, 
we define: Ij = Ij** x af = Ija
Ij** < Ij
Ij* = Ij
Step 2
Accounting for 
current vaccine 
schedule
ȜiȜi
as ȕij came 
from no 
vaccination
Step 3
Ȝi* yields 
paradoxical
Ij**
At the Excel®: Ij* x ȕij = Ȝi*
Step 1 – appendix 1
Step 3 – appendix 1
Step 5 – appendix 1
Ȝi
Ȝi
Ȝi*
ȕij
i: age-dependent transmission rate, Ij: number of infected by age group, Ija: adjusted number of infected by age group, βij: 
WAIFW matrix, af: adjusting factor, * (uppercase asterisk) means updated parameter.
Appendix 2. Adjusting factor (af): adjustment of compartment I to provide adequate λi. This shows why step 5 is required in 
the procedures described in Appendix 1.
